4.7 Review

Rifabutin: where do we stand in 2016?

期刊

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 71, 期 7, 页码 1759-1771

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jac/dkw024

关键词

-

向作者/读者索取更多资源

Rifabutin is a spiro-piperidyl-rifamycin structurally closely related to rifampicin that shares many of its properties. We attempted to address the reasons why this drug, which was recently recognized as a WHO Essential Medicine, still had a far narrower range of indications than rifampicin, 24 years after its launch. In this comprehensive review of the classic and more recent rifabutin experimental and clinical studies, the current state of knowledge about rifabutin is depicted, relying on specific pharmacokinetics, pharmacodynamics, antimicrobial properties, resistance data and side effects compared with rifampicin. There are consistent in vitro data and clinical studies showing that rifabutin has at least equivalent activity/efficacy and acceptable tolerance compared with rifampicin in TB and non-tuberculous mycobacterial diseases. Clinical studies have emphasized the clinical benefits of low rifabutin liver induction in patients with AIDS under PIs, in solid organ transplant patients under immunosuppressive drugs or in patients presenting intolerable side effects related to rifampicin. The contribution of rifabutin for rifampicin-resistant, but rifabutin-susceptible, Mycobacterium tuberculosis isolates according to the present breakpoints has been challenged and is now controversial. Compared with rifampicin, rifabutin's lower AUC is balanced by higher intracellular penetration and lower MIC for most pathogens. Clinical studies are lacking in non-mycobacterial infections.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Public, Environmental & Occupational Health

Abdominal Tuberculosis: Experience from Two Tertiary-Care Hospitals in the Paris Region

Ruxandra Calin, Anna Belkacem, Pauline Caraux-Paz, Mathilde Wagner, Heene Guillot, Nicolas Veziris, Stephane Jaureguiberry, Eric Caumes, Olivier Patey, Valerie Pourcher

Summary: Abdominal tuberculosis (ATB) is a rare disease and mainly affects young males of African descent. It is often characterized by lymph node and peritoneal involvement, with good treatment outcomes. The use of steroids in treatment remains controversial, with bacteriological confirmation being more common in diagnosis.

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2021)

Letter Respiratory System

Impact of the revised definition of extensively drug-resistant tuberculosis

Nicolas Veziris, Isabelle Bonnet, Florence Morel, Lorenzo Guglielmetti, Thomas Maitre, Laure Fournier Le Ray, Wladimir Sougakoff, Jerome Robert, Alexandra Aubry

EUROPEAN RESPIRATORY JOURNAL (2021)

Letter Respiratory System

Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies

Thomas Maitre, Lorenzo Guglielmetti, Nicolas Veziris

EUROPEAN RESPIRATORY JOURNAL (2021)

Article Respiratory System

Nontuberculous Mycobacteria under Scrutiny in the Geneva Area (2015-2020)

Rechana Vongthilath-Moeung, Jerome Plojoux, Antoine Poncet, Gesuele Renzi, Nicolas Veziris, Jacques Schrenzel, Jean-Paul Janssens

Summary: NTM strains in Western Switzerland exhibit geographical variability, predominantly affecting female patients with a median age of 62 and low BMI. Specific treatment was administered in 19% of patients with positive NTM cultures.

RESPIRATION (2021)

Letter Respiratory System

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Lorenzo Guglielmetti, Gunar Guenther, Claude Leu, Daniela Cirillo, Raquel Duarte, Alberto L. Garcia-Basteiro, Delia Goletti, Mateja Jankovic, Liga Kuksa, Florian P. Maurer, Frederic Mechai, Simon Tiberi, Frank van Leth, Nicolas Veziris, Christoph Lange

EUROPEAN RESPIRATORY JOURNAL (2022)

Editorial Material Respiratory System

Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Sophia B. Georghiou, Timothy C. Rodwell, Alexei Korobitsyn, Said H. Abbadi, Kanchan Ajbani, Jan-Willem Alffenaar, David Alland, Nataly Alvarez, Sonke Andres, Elisa Ardizzoni, Alexandra Aubry, Rossella Baldan, Marie Ballif, Ivan Barilar, Erik C. Bottger, Soumitesh Chakravorty, Pauline M. Claxton, Daniela M. Cirillo, Inaki Comas, Chris Coulter, Claudia M. Denkinger, Brigitta Derendinger, Edward P. Desmond, Jurriaan E. M. de Steenwinkel, Keertan Dheda, Andreas H. Diacon, David L. Dolinger, Kelly E. Dooley, Matthias Egger, Maha R. Farhat, Lanfranco Fattorini, Iris Finci, Laure Fournier Le Ray, Victoria Furio, Ramona Groenheit, Tawanda Gumbo, Scott K. Heysell, Doris Hillemann, Harald Hoffmann, Po-Ren Hsueh, Yi Hu, Hairong Huang, Alamdar Hussain, Farzana Ismail, Kiyohiko Izumi, Tomasz Jagielski, John L. Johnson, Priti Kambli, Kone Kaniga, G. H. R. Eranga Karunaratne, Meenu Kaushal Sharma, Peter M. Keller, Ellis C. Kelly, Margarita Kholina, Mikashmi Kohli, Katharina Kranzer, Ian F. Laurenson, Jason Limberis, S-Y Grace Lin, Yongge Liu, Alexandre Lopez-Gavin, Anna Lyander, Diana Machado, Elena Martinez, Faisal Masood, Satoshi Mitarai, Nomonde R. Mvelase, Stefan Niemann, Vladyslav Nikolayevskyy, Florian P. Maurer, Matthias Merker, Paolo Miotto, Shaheed Omar, Ralf Otto-Knapp, Moises Palaci, Juan Jose Palacios Gutierrez, Sharon J. Peacock, Charles A. Peloquin, Jennifer Perera, Catherine Pierre-Audigier, Suporn Pholwat, James E. Posey, Therdsak Prammananan, Leen Rigouts, Jaime Robledo, Neesha Rockwood, Camilla Rodrigues, Max Salfinger, Marcos C. Schechter, Marva Seifert, Sarah Sengstake, Thomas Shinnick, Natalia Shubladze, Vitali Sintchenko, Frederick Sirgel, Sulochana Somasundaram, Timothy R. Sterling, Andrea Spitaleri, Elizabeth Streicher, Philip Supply, Erik Svensson, Elisa Tagliani, Sabira Tahseen, Akiko Takaki, Grant Theron, Gabriela Torrea, Armand Van Deun, Annelies Van Rie, Dick van Soolingen, Roger Vargas, Amour Venter, Nicolas Veziris, Cristina Villellas, Miguel Viveiros, Robin Warren, Shu'an Wen, Jim Werngren, Robert J. Wilkinson, Caie Yang, Tingting Zhang, Danila Zimenkov, Nazir Ismail, Thomas Schon, Claudio U. Koser, Soudeh Ehsani, Jakko van Ingen, F. Ferda Yilmaz

EUROPEAN RESPIRATORY JOURNAL (2022)

Letter Infectious Diseases

Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study

Simone Tunesi, Damien Le Du, Gina Gualano, Joan-Pau Millet, Aliaksandr Skrahin, Graham Bothamley, Xavier Casas, Delia Goletti, Christoph Lange, Maria Musso, Fabrizio Palmieri, Valerie Pourcher, Christophe Rioux, Alena Skrahina, Nicolas Veziris, Dzmitry Viatushka, Mathilde Jachym-Frechet, Lorenzo Guglielmetti, Dhiba Marigot-Outtandy, Xavier Lescure, Marie Dubert, Yazdan Yazdanpanah, Eric Caumes, Pascaline Choinier, Elie Haddad, Jakub Kowalczyk, Helene Laurichesse, Olivier Lesens, Alexandra Aubry, Isabelle Bonnet, Florence Morel

JOURNAL OF INFECTION (2022)

Article Microbiology

Differential Performance of the FilmArray Meningitis/Encephalitis Assay To Detect Bacterial and Viral Pathogens in Both Pediatric and Adult Populations

Aurelie Schnuriger, Sophie Vimont, Alexandre Godmer, Joel Gozlan, Salah Gallah, Muriel Mace, Valerie Lalande, Kenda Saloum, Marine Perrier, Nicolas Veziris, Laurence Morand-Joubert

Summary: Based on our comparative analysis, we propose an algorithm for the use of both syndromic and specific assays, for an optimal care of the meningitis/encephalitis threat in adult and pediatric patients.

MICROBIOLOGY SPECTRUM (2022)

Article Immunology

Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB)

N. De Castro, F. Mechai, D. Bachelet, A. Canestri, V Joly, M. Vandenhende, D. Boutoille, M. Kerjouan, N. Veziris, J. M. Molina, N. Grall, P. Tattevin, C. Laouenan, Y. Yazdanpanah

Summary: The study shows that a combination of isoniazid, rifampicin, and pyrazinamide, based on early detection of isoniazid resistance using molecular testing, is noninferior to the recommended 4-drug regimen for tuberculosis treatment.

OPEN FORUM INFECTIOUS DISEASES (2022)

Article Microbiology

How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance

Thomas Maitre, Florence Morel, Florence Brossier, Wladimir Sougakoff, Jeremy Jaffre, Sokleaph Cheng, Nicolas Veziris, Alexandra Aubry

Summary: This study assessed the detection of ETH-R in 497 MDR-TB isolates and found a high mutation rate. The results do not support the association between ethR mutations and ETH resistance. The positive predictive value of the genotypic strategy to diagnose ETH-R can be improved by considering variants included in the WHO catalogue and other databases.

MICROORGANISMS (2022)

Article Microbiology

Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France

Isabelle Bonnet, Elie Haddad, Lorenzo Guglielmetti, Pascale Bemer, Louis Bernard, Anne Bourgoin, Rachel Brault, Gaud Catho, Eric Caumes, Lelia Escaut, Eric Fourniols, Mathilde Frechet-Jachym, Alice Gaudart, Helene Guillot, Barthelemy Lafon-Desmurs, Jean-Philippe Lanoix, Philippe Lanotte, Adrien Lemaignen, Benedicte Lemaire, Nadine Lemaitre, Christophe Michau, Philippe Morand, Faiza Mougari, Dhiba Marigot-Outtandy, Solene Patrat-Delon, Thomas Perpoint, Caroline Piau, Valerie Pourcher, Virginie Zarrouk, Valerie Zeller, Nicolas Veziris, Stephane Jaureguiberry, Alexandra Aubry

Summary: This study evaluated the diagnosis, management, and outcomes of multidrug-resistant tuberculosis strains (MDR-OATB) causing osteoarticular infection in France. Among 23 reported MDR-OATB cases, 91% of patients successfully completed treatment. However, further research is needed to determine the optimal treatment for MDR-OATB.

MICROORGANISMS (2022)

Article Multidisciplinary Sciences

Machine learning to improve the interpretation of intercalating dye-based quantitative PCR results

A. Godmer, J. Bigot, Q. Giai Gianetto, Y. Benzerara, N. Veziris, A. Aubry, J. Guitard, C. Hennequin

Summary: This study evaluated the contribution of Machine Learning (ML) approach in interpreting intercalating dye-based quantitative PCR (IDqPCR) signals for the diagnosis of mucormycosis. The results showed that the ML-based approach could accurately interpret IDqPCR curves, making the diagnosis of mucormycosis available for non-specialists in molecular diagnosis.

SCIENTIFIC REPORTS (2022)

Article Infectious Diseases

Epidemiology of infection by pulmonary non- tuberculous mycobacteria in French Guiana 2008-2018

Milene Chaptal, Claire Andrejak, Timothee Bonifay, Emmanuel Beillard, Genevieve Guillot, Stephanie Guyomard-Rabenirina, Magalie Demar, Sabine Trombert-Paolantoni, Veronique Jacomo, Emilie Mosnier, Nicolas Veziris, Felix Djossou, Loic Epelboin

Summary: This study is the first epidemiological study on non-tuberculous mycobacteria (PNTM) infections in French Guiana. The incidence of these infections in French Guiana is similar to that of other countries and metropolitan France, and is mainly caused by MAC and M.abscessus.

PLOS NEGLECTED TROPICAL DISEASES (2022)

Article Immunology

Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience

Raphael Chiron, Wouter Hoefsloot, Jakko Van Ingen, Helene Marchandin, Laurent Kremer, Helene Morisse-Pradier, Jeremy Charriot, Jean-Pierre Mallet, Jean-Louis Herrmann, Davide Caimmi, Johan Moreau, Yann Dumont, Sylvain Godreuil, Anne Bergeron, Margot Drevait, Elodie Bouzat-Rossigneux, Nicolas Terrail, Claire Andrejak, Nicolas Veziris, Dominique Grenet, Alexandre Coudrat, Emilie Catherinot

Summary: This study investigated the safety and efficacy of ALIS as an adjunct treatment for M abscessus lung infection. Among 26 patients with long-term follow-up data, a sputum culture conversion rate of 54% was achieved, and there was a significant association between patient treatment compliance and culture conversion and clinical outcomes.

OPEN FORUM INFECTIOUS DISEASES (2022)

Review Infectious Diseases

Optimizing the use of current antituberculosis drugs to overcome drug resistance in Mycobacterium tuberculosis

Thomas Maitre, Alain Baulard, Alexandra Aubry, Nicolas Veziris

Summary: Antibiotic-resistant tuberculosis poses a major threat to global tuberculosis control. Recent research has produced promising compounds that have the potential to change the game in treating multi-drug resistant tuberculosis. However, there are still obstacles preventing these molecules from being used as first-line drugs. Alternative strategies are being evaluated to optimize the utilization of existing antituberculosis agents, with a focus on enhancing the effectiveness of antibiotics against bacterial targets.

INFECTIOUS DISEASES NOW (2024)

暂无数据